BMRN

BMRN

USD

BioMarin Pharmaceutical Inc. Common Stock

$52.520-0.040 (-0.076%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$52.560

उच्च

$52.760

कम

$51.800

मात्रा

2.96M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

10.1B

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

2.34M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $51वर्तमान $52.520उच्च $73.51

संबंधित समाचार

Analyst Upgrades

Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical with a Outperform and lowers the price target from $95 to $88.

और देखें
Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88
Analyst Upgrades

Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80

Truist Securities analyst Joon Lee maintains BioMarin Pharmaceutical with a Buy and lowers the price target from $90 to $80.

और देखें
Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $90 to $70.

और देखें
Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70
Analyst Upgrades

Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80

Barclays analyst Gena Wang maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $86 to $80.

और देखें
Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical with a Neutral and lowers the price target from $60 to $55.

और देखें
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55
Analyst Upgrades

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $104 to $98.

PR Newswire

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with...

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।